The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas

References

• Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018 May;18(5):269–282.
   PubMed Web of Science ®Google Scholar
• Canning M, Guo G, Yu M, et al. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Front Cell Dev Biol. 2019;7:52.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576–582.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Larkins E, Blumenthal GM, Yuan W, et al. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist. 2017 Jul;22(7):873–878.
   PubMed Web of Science ®Google Scholar
• Guidi A, Codecà C, Ferrari D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol. 2018 Feb 13;35(3):37.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 Jul 15;7(1):184.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002. 2. Feb(2):116–126.
   Google Scholar
• Chikuma S. CTLA-4, an essential immune-checkpoint for T-cell activation. Curr Top Microbiol Immunol. 2017;410:99–126.
   PubMed Web of Science ®Google Scholar
• Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000 Jul 17;192(2):295–302.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb;39(1):98–106.
   PubMed Web of Science ®Google Scholar
• Mo X, Zhang H, Preston S, et al. Interferon-γ signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Cancer Res. 2018 Jan 15;78(2):436–450.
   PubMed Web of Science ®Google Scholar
• Contardi E, Palmisano GL, Tazzari PL, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005 Nov 20;117(4):538–550.
   PubMed Web of Science ®Google Scholar
• Hathcock KS, Laszlo G, Pucillo C, et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994 Aug 1;180(2):631–640.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993 Nov 5;262(5135):909–911.
   PubMed Web of Science ®Google Scholar
• Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001 Dec;1(3):220–228.
   PubMed Web of Science ®Google Scholar
• Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999 Jan 21;397(6716):263–266.
   PubMed Web of Science ®Google Scholar
• Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001 Jan 4;409(6816):97–101.
   PubMed Web of Science ®Google Scholar
• McAdam AJ, Chang TT, Lumelsky AE, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol. 2000 Nov 1;165(9):5035–5040.
   PubMed Web of Science ®Google Scholar
• Beier KC, Hutloff A, Dittrich AM, et al. Induction, binding specificity and function of human ICOS. Eur J Immunol. 2000 Dec;30(12):3707–3717.
   PubMed Web of Science ®Google Scholar
• Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 2000 Jul;13(1):95–105.
   PubMed Web of Science ®Google Scholar
• McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature. 2001 Jan 4;409(6816):102–105.
   PubMed Web of Science ®Google Scholar
• Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature. 2001 Jan 4;409(6816):105–109.
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012 May 29;13(7):484–492.
   PubMed Web of Science ®Google Scholar
• Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin. 2010 Nov-Dec;60(6):376–392. Epub 2010 Oct 19.
   PubMed Web of Science ®Google Scholar
• Schmidl C, Delacher M, Huehn J, et al. Epigenetic mechanisms regulating T-cell responses. J Allergy Clin Immunol. 2018 Sep;142(3):728–743.
   PubMed Web of Science ®Google Scholar
• Ghoneim HE, Zamora AE, Thomas PG, et al. Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends Mol Med. 2016 Dec;22(12):1000–1011.
   PubMed Web of Science ®Google Scholar
• Gevensleben H, Holmes EE, Goltz D, et al. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016 Nov 29;7(48):79943–79955.
   PubMedGoogle Scholar
• Goltz D, Gevensleben H, Dietrich J, et al. Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology. 2016 Sep 2;5(10):e1221555.
   PubMed Web of Science ®Google Scholar
• Micevic G, Thakral D, McGeary M, et al. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival. Pigment Cell Melanoma Res. 2019 May;32(3):435–440.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Dietrich J, et al. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget. 2017 Jun 20;8(25):41011–41020.
   PubMedGoogle Scholar
• Goltz D, Gevensleben H, Dietrich J, et al. PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology. 2016 Nov 10;6(1):e1257454.
   PubMed Web of Science ®Google Scholar
• Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019 Mar;25(3):389–402.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016 Dec;17(12):e542–e551.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016 May;16(5):275–287.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017 Aug 1;127(8):2930–2940.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018 Apr 17;48(4):812–830.e14.
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019 Mar;19(3):133–150.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Vogt TJ, et al. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight. 2018 Jul 12;3(13):96793.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Lesche R, Tetzner R, et al. Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem. 2009 May;57(5):477–489.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Hasinger O, Bañez LL, et al. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar;15(2):270–279.
   PubMed Web of Science ®Google Scholar
• Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin Ther Targets. 2018 Apr;22(4):343–351.
   PubMed Web of Science ®Google Scholar
• Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011 Aug 15;71(16):5445–5454.
   PubMed Web of Science ®Google Scholar
• Ng Tang D, Shen Y, Sun J, et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013 Oct;1(4):229–234.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Calabrò L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother. 2013 Jun;62(6):1021–1028.
   PubMed Web of Science ®Google Scholar
• Haile ST, Bosch JJ, Agu NI, et al. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 2011 Jun 15;186(12):6822–6829.
   PubMed Web of Science ®Google Scholar
• Haile ST, Dalal SP, Clements V, et al. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013 Sep 1;191(5):2829–2836.
   PubMed Web of Science ®Google Scholar
• Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 2006 Feb 15;66(4):2442–2450.
   PubMed Web of Science ®Google Scholar
• Foreman KE, Wrone-Smith T, Krueger AE, et al. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi’s sarcoma tumor cell line induces differential T-cell activation and proliferation. Clin Immunol. 1999 Jun;91(3):345–353.
   PubMed Web of Science ®Google Scholar
• Singh NP, Yolcu ES, Taylor DD, et al. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 2003 Jul 15;63(14):4067–4073.
   PubMed Web of Science ®Google Scholar
• Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016 Oct 20;1(17):e89829.
   PubMed Web of Science ®Google Scholar
• de Ruiter EJ, Ooft ML, Devriese LA, et al. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 2017 Aug 9;6(11):e1356148.
   PubMed Web of Science ®Google Scholar
• Sailer V, Sailer U, Bawden EG, et al. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature. EBioMedicine. 2019Oct;48:341–352.
   PubMed Web of Science ®Google Scholar
• Salvi S, Fontana V, Boccardo S, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2012 Sep;61(9):1463–1472.
   PubMed Web of Science ®Google Scholar
• Huang PY, Guo SS, Zhang Y, et al. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. Oncotarget. 2016 Mar 15;7(11):13060–13068.
   PubMedGoogle Scholar
• Santoni G, Amantini C, Morelli MB, et al. High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget. 2018 Mar 30;9(24):16665–16677.
   PubMedGoogle Scholar
• Zhang Y, Luo Y, Qin SL, et al. The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology. 2016 Mar 10;5(5):e1141857.
   PubMed Web of Science ®Google Scholar
• Faget J, Sisirak V, Blay JY, et al. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells. Oncoimmunology. 2013 Mar 1;2(3):e23185.
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Vano Y, et al. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2017 Aug 1;23(15):4416–4428.
   PubMed Web of Science ®Google Scholar
• Rincon-Orozco B, Halec G, Rosenberger S, et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 2009 Nov 15;69(22):8718–8725.
   PubMed Web of Science ®Google Scholar
• Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol. 2011 Nov;85(21):11372–11380.
   PubMed Web of Science ®Google Scholar
• Cicchini L, Blumhagen RZ, Westrich JA, et al. High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes. Sci Rep. 2017 Jun 16;7(1):3633.
   PubMedGoogle Scholar
• Cicchini L, Westrich JA, Xu T, et al. Suppression of antitumor immune responses by human papillomavirus through epigenetic downregulation of CXCL14. MBio. 2016 May 3;7(3):e00270–16.
   PubMed Web of Science ®Google Scholar
• Kuss-Duerkop SK, Westrich JA, Pyeon D. DNA tumor virus regulation of host dna methylation and its implications for immune evasion and oncogenesis. Viruses. 2018 Feb 13;10(2):E82.
   PubMed Web of Science ®Google Scholar
• Minarovits J, Demcsák A, Banati F, et al. Epigenetic Dysregulation in Virus-Associated Neoplasms. Adv Exp Med Biol. 2016;879:71–90.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic Interactions in cancer. Cell. 2016 Jul 28;166(3):740–754.
   PubMed Web of Science ®Google Scholar
• Lechner M, Fenton T, West J, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 2013 Feb 5;5(2):15.
   PubMedGoogle Scholar
• Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011 Aug 4;12: 323.
   PubMed Web of Science ®Google Scholar